Inhibikase Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Company Name | ||
| Date: March 27, 2024 | By: | /s/ MILTON H. WERNER, Ph.D. |
|---|---|---|
| Milton H. Werner, Ph.D. | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ MILTON H. WERNER, Ph.D. | Chief Executive Officer and Director (Principal Executive Officer) | March 27, 2024 |
| Milton H. Werner, Ph.D. | ||
| /s/ JOSEPH FRATTAROLI | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 27, 2024 |
| Joseph Frattaroli | ||
| /s/ GISELE DION | Director | March 27, 2024 |
| Gisele Dion | ||
| /s/ ROY FREEMAN, M.D. | Director | March 27, 2024 |
| Roy Freeman, M.D. | ||
| /s/ PAUL GRINT, M.D. | Director | March 27, 2024 |
| Paul Grint, M.D. | ||
| /s/ DENNIS BERMAN | Director | March 27, 2024 |
| Dennis Berman | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.